STAGE IV RENAL CELL CANCER AJCC V8
Clinical trials for STAGE IV RENAL CELL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL CELL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL CELL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy targets Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:27 UTC
-
Zapping cancer spots: radiation may replace chemo for some kidney patients
Disease control TerminatedThis study tests whether focused, high-dose radiation (SBRT) can control kidney cancer that has spread to a few spots in the body. The goal is to see if this approach can delay or avoid the need for systemic treatments like chemotherapy or immunotherapy. About 123 participants wi…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:26 UTC
-
New drug combo shows promise in shrinking advanced kidney tumors before surgery
Disease control OngoingThis study tests whether giving two drugs—lenvatinib and pembrolizumab—before surgery can shrink tumors in people with advanced kidney cancer that hasn't spread to other organs. About 18 participants will receive the combination for 12 weeks, then have surgery. The main goal is t…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 26, 2026 04:25 UTC
-
Two-Drug combo aims to starve and attack advanced cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:25 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug (DS3201) combined with an immunotherapy (ipilimumab) in people with advanced prostate, bladder, or kidney cancer that has spread. The goal is to find the safest dose and see if the combination can help control the cancer. About 65 adults wi…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:23 UTC
-
New hope for kidney cancer: two drug regimens battle after immunotherapy fails
Disease control OngoingThis study tests two different drug treatments for people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of two drugs (lenvatinib plus everolimus) or a single drug (cabozantini…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:18 UTC
-
Could a tropical berry boost immunotherapy against kidney cancer?
Disease control OngoingThis early-stage trial tests whether adding camu camu, a prebiotic berry, to standard immunotherapy (nivolumab and ipilimumab) can improve treatment for advanced kidney cancer. About 31 people with metastatic clear-cell or sarcomatoid kidney cancer will receive the combination. T…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:17 UTC
-
Radiation boost may extend life for kidney cancer patients
Disease control OngoingThis study tests whether giving precise, high-dose radiation (SAbR) to tumors before standard treatment (immunotherapy or pills) helps people with kidney cancer that has spread to 2-5 places in the body live longer. About 472 adults with this type of advanced kidney cancer will t…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 04:16 UTC
-
Gut bacteria boost may help kidney cancer drugs work better
Disease control OngoingThis early-phase study looks at whether adding a probiotic called CBM588 to the usual two-drug treatment (cabozantinib and nivolumab) can improve outcomes for people with advanced kidney cancer that has spread. The probiotic is meant to increase helpful gut bacteria, which may he…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
New combo shows promise in advanced kidney cancer trial
Disease control OngoingThis phase 3 trial tests whether adding the drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) helps people with advanced kidney cancer live longer. About 1,175 adults with kidney cancer that has spread will take part. The goal is to see if the combination wor…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:11 UTC
-
Targeted drug shows promise for rare genetic cancer type
Disease control OngoingThis study tests a drug called adavosertib in 18 adults with advanced solid tumors that lack the SETD2 gene. The drug works by blocking enzymes that help cancer cells grow. Researchers want to see if it can shrink tumors or keep them stable for at least 6 months.
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
Could a radioactive drug plus standard therapy ease bone pain in advanced kidney cancer?
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to the usual treatment (cabozantinib) helps people with advanced kidney cancer that has spread to the bones. About 134 adults with any type of kidney cancer and bone metastases will be randomly assigned to receive ca…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether adding the immunotherapy drug atezolizumab to the standard drug cabozantinib works better than cabozantinib alone for people with advanced papillary kidney cancer that has spread. About 200 participants will receive either the combination or cabozantinib …
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
Personalized cell therapy trial for advanced cancers withdrawn before enrollment
Disease control TerminatedThis early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New combo therapy shows promise for rare kidney cancer
Disease control OngoingThis study tests whether combining two drugs—axitinib (which blocks cancer cell growth) and nivolumab (which helps the immune system attack cancer)—works better than nivolumab alone for a rare type of kidney cancer called TFE/translocation renal cell carcinoma (tRCC). The trial i…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
Head-to-Head drug battle offers hope for rare kidney cancer
Disease control OngoingThis study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 par…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
Tighter BP control may shield cancer patients from heart and kidney harm
Disease control OngoingThis study looks at whether keeping blood pressure very low (below 120 mmHg) is better than the usual target (below 140 mmHg) for people with advanced kidney or thyroid cancer who are starting certain targeted cancer drugs. The goal is to reduce the risk of heart and kidney probl…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 20, 2026 12:08 UTC
-
Promising drug cocktail targets rare, aggressive kidney cancer
Disease control OngoingThis study tests a combination of three drugs (ixazomib, gemcitabine, and doxorubicin) in 30 people with a rare and aggressive kidney cancer that has spread. The goal is to see if the treatment can shrink tumors or stop them from growing. Participants receive the drugs in cycles,…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Can a mindfulness app ease the fear of advanced kidney cancer?
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help people with metastatic kidney cancer feel better emotionally and improve their quality of life. About 21 adults with advanced kidney cancer who are on immunotherapy and have moderate to high fear of their…
Matched conditions: STAGE IV RENAL CELL CANCER AJCC V8
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated May 22, 2026 13:53 UTC